IP Library Granted Patent US 11,819,486
Granted Patent B2
US 11,819,486 · App. 17/380,900 · Granted Nov 21, 2023

Composition for external use on skin for inflammatory diseases

Inventors: Jiro Takeo (Hachioji, JP); Hiroyuki Kawahara (Hachioji, JP)
Assignee: NISSUI CORPORATION
A61K31/202A61K9/0014A61K31/232A61K31/683A61K31/685A61K31/7032A61K47/06A61P17/00A61P17/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,819,486
App. No.
17/380,900
Granted
Nov 21, 2023
Kind
B2
Abstract

[Problem] To provide a composition for external skin use that has anti-inflammatory and antiallergic activity, and is very safe. [Solution] A composition for external skin use for inflammatory diseases contains dihomo-gamma-linolenic acid (DGLA) as the active ingredient thereof. It is preferable for the DGLA to be present as a glyceride, a phospholipid, or an alkyl ester. The amount of DGLA contained in the composition for external use is 0.1-50 wt %.

Claims (12)

1. A method of treating inflammatory disease comprising

administering topically, to the skin of a patient in need thereof, an effective amount of dihomo-γ-linolenic acid (DGLA),

wherein the DGLA is applied continuously for at least 14 consecutive days to an area affected by the inflammatory disease, and

wherein the DGLA is administered in the form of an ointment comprising DGLA containing oil and zinc oxide.

2. The method according to claim 1 , wherein the DGLA is provided in the form of an oil derived from a culture of micro-organisms of genus Mortierella.

3. The method according to claim 1 , wherein the DGLA is in the form of any one of a glyceride, a phospholipid, a glycolipid, an alkyl ester, a salt, or a free fatty acid.

4. The method according to claim 3 , wherein the glyceride is a triglyceride, a diglyceride, or a monoglyceride.

5. The method according to claim 3 , wherein the alkyl ester is an ester with a lower C 1-4 alcohol.

6. The method according to claim 3 , wherein the phospholipid is diacylglycerophospholipid or lysoacylglycerophospholipid.

7. The method according to claim 1 , wherein the DGLA is administered in a composition containing 0.01 to 50 wt % of the DGLA.

8. The method according to claim 1 , wherein the inflammatory disease is an inflammatory skin disease.

9. The method according to claim 8 , wherein the inflammatory disease is atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis, psoriasis, rheumatism, or lupus.

Assignments (2)
CHANGE OF NAME Recorded Aug 22, 2023
From: NIPPON SUISAN KAISHA, LTD.
To: NISSUI CORPORATION
Reel/Frame 064908/0748 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2021
From: TAKEO, JIRO; KAWAHARA, HIROYUKI
To: NIPPON SUISAN KAISHA, LTD.
Reel/Frame 056934/0668 →
Priority Claims (1)
JP 2011-107512 · May 12, 2011 · national
Continuity (4)
Continuation 16689689 · Nov 20, 2019
Continuation 14928369 · Oct 30, 2015
Continuation 14117330
Related Publication 20210346330A1 · Nov 11, 2021